GILEAD SCIENCES INC (GILD)
US3755581036 - Common Stock
Undervalued Icons: 3 Household Names Trading at Steep Discounts
Three of Wall Street's undervalued stocks could provide a unique blend of stability and long-term growth potential.
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.
Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know
Gilead Sciences (GILD) closed the most recent trading day at $66.76, moving +0.91% from the previous trading session.
Interesting GILD Put And Call Options For July 19th
Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Gilead Sciences (GILD) closed at $66.16 in the latest trading session, marking a -1.15% move from the prior day.
Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why the dividend investor may take a look at NASDAQ:GILD.
Uncovering Dividend Opportunities with GILEAD SCIENCES INC (NASDAQ:GILD).
KKR Moves Up In Market Cap Rank, Passing Gilead Sciences
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?
Should You Buy the 3 Highest-Paying Dividend Stocks in the Nasdaq?
Dividend stocks can be a smart way to ride out market volatility.
GILD May 31st Options Begin Trading
Biotech Innovations Paving the Way in Breast Cancer Fight
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:GTHX),(NASDAQ:AZN),(NASDAQ:HOLX) EQNX::TICKER_END
Biotech Innovations Paving the Way in Breast Cancer Fight
/PRNewswire/ -- USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases,...
3 Stocks at 52-Week Lows Poised for a Powerful Rebound
Starbucks, Gilead, and Vale are three stocks at 52-week lows that show signs of recovery potential and long-term growth prospects.
Relative Strength Alert For Gilead Sciences
Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
3 No-Brainer Dividend Stocks to Buy in April
Income investors will find a lot to like about these stocks.
Got $5,000? These 3 High-Yielding Dividend Stocks Are Trading Near Their 52-Week Lows
All of these stocks pay generous dividends that income investors will appreciate.
May 24th Options Now Available For Gilead Sciences (GILD)
Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know
Gilead Sciences (GILD) closed at $72.09 in the latest trading session, marking a -1.08% move from the prior day.
5 Healthcare Stocks to Buy for 2024
Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up.